Lysophospholipids are potential biomarkers of ovarian cancer

Rebecca Sutphen, Yan Xu, George D. Wilbanks, James Fiorica, Edward C. Grendys, James P. LaPolla, Hector Arango, Mitchell S. Hoffman, Martin Martino, Katie Wakeley, David Griffin, Rafael W. Blanco, Alan B. Cantor, Yi Jin Xiao, Jeffrey P. Krischer

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1- phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1185-1191
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number7
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Lysophospholipids
Ovarian Neoplasms
Biomarkers
Lysophosphatidylcholines
Electrospray Ionization Mass Spectrometry
lysophosphatidic acid
Healthy Volunteers
Sensitivity and Specificity

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Sutphen, R., Xu, Y., Wilbanks, G. D., Fiorica, J., Grendys, E. C., LaPolla, J. P., ... Krischer, J. P. (2004). Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 13(7), 1185-1191.

Lysophospholipids are potential biomarkers of ovarian cancer. / Sutphen, Rebecca; Xu, Yan; Wilbanks, George D.; Fiorica, James; Grendys, Edward C.; LaPolla, James P.; Arango, Hector; Hoffman, Mitchell S.; Martino, Martin; Wakeley, Katie; Griffin, David; Blanco, Rafael W.; Cantor, Alan B.; Xiao, Yi Jin; Krischer, Jeffrey P.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 7, 07.2004, p. 1185-1191.

Research output: Contribution to journalArticle

Sutphen, R, Xu, Y, Wilbanks, GD, Fiorica, J, Grendys, EC, LaPolla, JP, Arango, H, Hoffman, MS, Martino, M, Wakeley, K, Griffin, D, Blanco, RW, Cantor, AB, Xiao, YJ & Krischer, JP 2004, 'Lysophospholipids are potential biomarkers of ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 7, pp. 1185-1191.
Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, LaPolla JP et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiology Biomarkers and Prevention. 2004 Jul;13(7):1185-1191.
Sutphen, Rebecca ; Xu, Yan ; Wilbanks, George D. ; Fiorica, James ; Grendys, Edward C. ; LaPolla, James P. ; Arango, Hector ; Hoffman, Mitchell S. ; Martino, Martin ; Wakeley, Katie ; Griffin, David ; Blanco, Rafael W. ; Cantor, Alan B. ; Xiao, Yi Jin ; Krischer, Jeffrey P. / Lysophospholipids are potential biomarkers of ovarian cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 7. pp. 1185-1191.
@article{204b9eab13124930a347fac49e0d8dab,
title = "Lysophospholipids are potential biomarkers of ovarian cancer",
abstract = "Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1- phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1{\%} correct classification, 91.1{\%} sensitivity, and 96.3{\%} specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.",
author = "Rebecca Sutphen and Yan Xu and Wilbanks, {George D.} and James Fiorica and Grendys, {Edward C.} and LaPolla, {James P.} and Hector Arango and Hoffman, {Mitchell S.} and Martin Martino and Katie Wakeley and David Griffin and Blanco, {Rafael W.} and Cantor, {Alan B.} and Xiao, {Yi Jin} and Krischer, {Jeffrey P.}",
year = "2004",
month = "7",
language = "English (US)",
volume = "13",
pages = "1185--1191",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Lysophospholipids are potential biomarkers of ovarian cancer

AU - Sutphen, Rebecca

AU - Xu, Yan

AU - Wilbanks, George D.

AU - Fiorica, James

AU - Grendys, Edward C.

AU - LaPolla, James P.

AU - Arango, Hector

AU - Hoffman, Mitchell S.

AU - Martino, Martin

AU - Wakeley, Katie

AU - Griffin, David

AU - Blanco, Rafael W.

AU - Cantor, Alan B.

AU - Xiao, Yi Jin

AU - Krischer, Jeffrey P.

PY - 2004/7

Y1 - 2004/7

N2 - Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1- phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

AB - Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting. Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed. Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1- phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels. Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=3142660497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142660497&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1185

EP - 1191

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -